Search
Lilly has unveiled the outcomes of its Phase 3 study on orforglipron, a once-daily oral small molecule GLP-1 (glucagon-like peptide-1) drug. The study demonstrated that orforglipron reduced the average glycated hemoglobin (HbA1c) levels by 1.3% to 1.6% in adult patients with type 2 diabetes across all dose groups, with notable improvements observed within just four weeks. Furthermore, the high-dose group achieved an average weight loss of 7.3 kilograms by week 40. As the first oral non-peptide GLP-1 receptor agonist to successfully conclude a Phase 3 study without any dietary or hydration restrictions, orforglipron marks a significant milestone. Lilly intends to submit a marketing application for orforglipron by the end of this year for weight management and anticipates filing an application for its use in treating type 2 diabetes by 2026.
-
C114 Communication Network -
Communication Home
